Market research
EV0.F Evoke Pharma, Inc
F EUR Healthcare
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- 0.0%
- Beta
- 0.74
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- 0.0%
- Beta
- 0.74
About
About Evoke Pharma, Inc
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Research context
Evoke Pharma, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EV0.F discussion.
5 years, 7 months ago
Evoke Pharma, Inc is currently in a long term downtrend where the price is trading 53.0% below its 200 day moving average.
From a valuation standpoint, the stock is 63.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 2145.2.
Evoke Pharma, Inc's total revenue rose by inf% to $23K since the same quarter in the previous year.
Its net income has dropped by 59.9% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 49.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Evoke Pharma, Inc gets an overall score of 1/5.